Skin Disorders News

The risk of developing alopecia areata increases when both seasonal and food allergies are present, according to a study published in The European Journal of Allergy and Clinical Immunology.

While the art of tattooing has been present for centuries, the medical implications are only recently coming to light with modern medicine.

KalVista Pharmaceuticals Inc. submitted a new drug application to the FDA for the approval of sebetralstat for patients aged 12 years and older with hereditary angioedema, according to a company press release.

Instead of patch testing with all allergens in any given group, using an optimized subset of allergens to test for allergic contact dermatitis can provide a similar level of care at a reduced cost, according to a study.

Seborrheic dermatitis is more prevalent across the world than previously believed, with a global pooled prevalence of 4.38%, according to a comprehensive meta-analysis.

Enrollment has been completed in a phase 2 clinical trial for the evaluation of bempikibart as a treatment for adults with persistent, moderate to severe atopic dermatitis, Q32 Bio announced in a press release.

The FDA has approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older, Arcutis announced in a press release.

The FDA is working to finalize an action letter regarding Arcutis’ supplemental new drug application for roflumilast cream 0.15% indicated for atopic dermatitis, the company announced in a press release.

Dupilumab treatment was associated with the reduced risk for atopic march progression in pediatric and adolescent patients with atopic dermatitis, according to a study.

A picture-based scorecard with multiple skin tones facilitated the assessment of atopic dermatitis among infants, according to a study published in Annals of Allergy, Asthma & Immunology.